Press Detail

PRESS RELEASE

Biotest AG: Annual general meeting approves dividend

- Distribution of EUR 0.44 per ordinary share and EUR 0.50 per preference share

- Dr. Alessandro Banchi elected as new Supervisory Board Chairman

Dreieich / Frankfurt a. M., 10 May 2012. At the annual general meeting (AGM) held on 10 May 2012 in Frankfurt am Main shareholders of Biotest AG approved payment of a dividend. With 81,49 percent of the share capital represented at the meeting, a payment of EUR 0.44 per ordinary share and EUR 0.50 per preference share met with wide endorsement. This equates to a dividend increase of 15.8% relative to last year for ordinary shares and 13.6% for preference shares. The overall distribution will amount to EUR 5.5 million.

The AGM also took a decision on the new composition of the Supervisory Board whose term of office expired at the conclusion of the meeting. At his own request, the previous Supervisory Board Chairman Dr. Thorlef Spickschen does not stand again for the Board. He is succeeded by the new Supervisory Board member Dr. Alessandro Banchi, who was elected along with existing members Dr. Cathrin Schleussner and Thomas Jakob by a large majority. Another new member, Dr. Christoph Schröder, was also widely endorsed in place of Professor Dr. Marbod Muff who is stepping down. Jürgen Heilmann and Kerstin Birkhahn will again join the Board as employee representatives for a further five years.

Professor Dr. Gregor Schulz, Chairman of the Management Board of the Biotest Group, thanked the retiring Chairman of the Supervisory Board, Dr. Thorlef Spickschen, warmly for his commitment to the company's development. 'Since taking office in 2005, Dr. Spickschen has been a valuable supporter of Biotest with his extensive experience of the pharmaceutical industry. Under his chairmanship important decisions for the future of Biotest have been taken e.g. the acquisition of Nabi Biologics in 2007. Both the Management and Supervisory Boards would therefore like to thank him sincerely for his extraordinary commitment,' said Professor Dr. Schulz. Professor Dr. Marbod Muff, who did not stand again for the Supervisory Board, was also given a warm send-off: 'Professor Dr. Muff has supported the development of Biotest since his appointment in 2008. His wide expertise of finance and accountancy issues in particular has been highly valued but also his input for the business development have been greatly appreciated,' Professor Dr. Schulz concluded.

The annual general meeting attended by around 89 shareholders and guests also formally discharged the members of the Management and Supervisory Boards for financial year 2011 and endorsed all of the other agenda items by a large majority.

The full text of the address given by Professor Gregor Schulz at the AGM is available at: http://www.biotest.de/ww/de/pub/investor_relations/ hauptversammlung.cfm.

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest

Biotest is a provider of pharmaceutical and biotherapeutic drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of application of clinical immunology, haematology and intensive medicine. In its Plasma Protein segment, Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In the Biotherapeutic segment, Biotest researches into the clinical development of monoclonal antibodies, including in the indications of rheumatoid arthritis and cancer of plasma cells. Biotest has more than 1.600 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, München, Stuttgart